SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.54 CNY | +1.19% |
|
-1.19% | -3.43% |
| Apr. 23 | Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income | MT |
| Apr. 23 | Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,858 | 29,138 | 30,220 | 36,225 | 35,644 | 34,018 | - | - |
| Enterprise Value (EV) 1 | 20,089 | 28,673 | 27,054 | 33,743 | 34,373 | 33,490 | 32,489 | 33,354 |
| P/E ratio | 29.3 x | 472 x | 54.6 x | 56.6 x | 62.8 x | 54.7 x | 44.2 x | 37.8 x |
| Yield | 2.51% | - | 1.46% | 1.52% | 1.53% | 0.67% | 1.36% | 1.52% |
| Capitalization / Revenue | 4.67 x | 10.6 x | 9.88 x | 10.4 x | 10.6 x | 8.52 x | 7.26 x | 6.2 x |
| EV / Revenue | 4.49 x | 10.5 x | 8.85 x | 9.69 x | 10.2 x | 8.39 x | 6.94 x | 6.08 x |
| EV / EBITDA | 18.4 x | 83.6 x | 30 x | 31.7 x | 33.9 x | 32.1 x | 27 x | 24.3 x |
| EV / FCF | - | 39.1 x | - | 90.6 x | - | 57.9 x | 44.1 x | 43.9 x |
| FCF Yield | - | 2.56% | - | 1.1% | - | 1.73% | 2.27% | 2.28% |
| Price to Book | 3.21 x | 5.38 x | 3.79 x | 4.61 x | 4.54 x | 4.13 x | 4.04 x | 3.86 x |
| Nbr of stocks (in thousands) | 1,046,016 | 1,028,513 | 1,106,137 | 1,102,746 | 1,091,359 | 1,091,359 | - | - |
| Reference price 2 | 19.94 | 28.33 | 27.32 | 32.85 | 32.66 | 31.17 | 31.17 | 31.17 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,470 | 2,739 | 3,058 | 3,482 | 3,365 | 3,992 | 4,684 | 5,486 |
| EBITDA 1 | 1,093 | 343.2 | 900.4 | 1,064 | 1,013 | 1,043 | 1,202 | 1,374 |
| EBIT 1 | 846.1 | 79.22 | 586.2 | 727.4 | 656 | 660.3 | 894.4 | 1,037 |
| Operating Margin | 18.93% | 2.89% | 19.17% | 20.89% | 19.49% | 16.54% | 19.1% | 18.9% |
| Earnings before Tax (EBT) 1 | 851.3 | 56.74 | 599.8 | 713.7 | 641.8 | 701.4 | 901.7 | 1,049 |
| Net income 1 | 715.2 | 60.86 | 533.7 | 636.9 | 580.1 | 633 | 785.9 | 921.9 |
| Net margin | 16% | 2.22% | 17.45% | 18.29% | 17.24% | 15.86% | 16.78% | 16.81% |
| EPS 2 | 0.6800 | 0.0600 | 0.5000 | 0.5800 | 0.5200 | 0.5700 | 0.7050 | 0.8250 |
| Free Cash Flow 1 | - | 732.8 | - | 372.4 | - | 578.6 | 736.1 | 760.4 |
| FCF margin | - | 26.76% | - | 10.7% | - | 14.49% | 15.72% | 13.86% |
| FCF Conversion (EBITDA) | - | 213.53% | - | 34.99% | - | 55.45% | 61.25% | 55.33% |
| FCF Conversion (Net income) | - | 1,203.91% | - | 58.47% | - | 91.4% | 93.66% | 82.48% |
| Dividend per Share 2 | 0.5000 | - | 0.4000 | 0.5000 | 0.5000 | 0.2100 | 0.4250 | 0.4750 |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 1 | 0.1200 | 0.2200 | 0.0900 | 0.1800 | 0.0900 | 0.1900 | 0.1100 | 0.1300 | 0.0900 | 0.1800 | 0.1600 | 0.1400 | 0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/28/22 | 4/18/22 | 8/9/22 | 10/24/22 | 3/28/23 | 4/18/23 | 8/24/23 | 10/30/23 | 3/25/24 | 4/22/24 | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 769 | 465 | 3,166 | 2,482 | 1,271 | 528 | 1,528 | 664 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 733 | - | 372 | - | 579 | 736 | 760 |
| ROE (net income / shareholders' equity) | 11.1% | 1.03% | 7.6% | 8.13% | 7.35% | 7.69% | 9.23% | 10.3% |
| ROA (Net income/ Total Assets) | 9.15% | 0.83% | 6.6% | 6.71% | - | 6.95% | 8.3% | 8.65% |
| Assets 1 | 7,819 | 7,324 | 8,081 | 9,500 | - | 9,108 | 9,469 | 10,658 |
| Book Value Per Share 2 | 6.200 | 5.270 | 7.210 | 7.120 | 7.190 | 7.540 | 7.710 | 8.080 |
| Cash Flow per Share 2 | 1.440 | 1.310 | 1.110 | 0.8700 | 0.7500 | 1.500 | 0.7000 | 1.070 |
| Capex 1 | - | 642 | 481 | 598 | 670 | 481 | 501 | 502 |
| Capex / Sales | - | 23.43% | 15.72% | 17.18% | 19.92% | 12.05% | 10.71% | 9.16% |
| Announcement Date | 2/28/20 | 3/29/21 | 3/28/22 | 3/28/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
31.17
CNY
Average target price
37
CNY
Spread / Average Target
+18.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.56% | 4.71B | |
| +18.67% | 43.74B | |
| +21.99% | 22.26B | |
| +16.41% | 14.9B | |
| +9.03% | 13.39B | |
| +40.48% | 12.12B | |
| -9.64% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.47B |
- Stock Market
- Equities
- 002294 Stock
- Financials Shenzhen Salubris Pharmaceuticals Co., Ltd.